Open AccessNovel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohort
Author(s) -
Yuan Li,
Zuhua Chen,
Long Wu,
Weiping Tao
Publication year - 2020
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm.2020.03.163
Subject(s) - medicine , hazard ratio , oncology , cancer , nonsynonymous substitution , lung cancer , colorectal cancer , cohort , immunotherapy , mutation , biomarker , gene , biology , genetics , confidence interval , genome
The novel TMS55 might be better than TMB as a biomarker for patients treated with ICIs. The easy calculation and universal cutoff value of TMS55 will not be affected across platforms and is feasible in clinical settings, which may greatly promote its application in the clinic with further validation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom